State of California

Department of Consumer Affairs Medical Board of California

Date: April 11, 2007

## Memoranndum

To:

Frank Valine

**Diversion Program Administrator** 

From:

Letitia Robinson

Collection System Manager

Subject: Collection System Status Report for January – March 2007

Attached are the charts reporting the collective test results for UDS samples taken during the 3<sup>rd</sup> Quarter, January – March of FY 2006/2007.

The majority of positive results continue to be a result of approved prescriptions for Naltrexone taken by some participants, or medications prescribed for surgery. One participant still shows positive results on occasion as a result of sugar imbalances from his diabetes. There were five new participants who had initial positive tests and were sent to treatment.

Four participants with positive UDS samples were determined to have relapsed (one had self-reported): two were terminated from the program, and two were ordered inpatient treatment, as indicated on the quarterly report.

During this reporting period the "Turn Around Time" as reported by Quest lab:

	Date of collection to lab receipt	Lab receipt to results reported	Total Time
Averages:	4.2	2.4	6.5
	days	days	days

**Attachments** 

## Data on Urine Tests Results – 3<sup>rd</sup> Quarter January – March 2007

	TEST RES		<b></b>	-		
<b>Month</b> 2007	Total # of Tests	Total Positive Results	Number of Positives	Comments		
January	841	78	1 4 4 64 1 2 1	Participant relapsed. (#1 on Relapse Report) One participant ongoing relapse from December 2006. Approved prescriptions other than Naltrexone by case manager. Approved prescriptions by case manager for Naltreoxne. New participant, initial positive – sent to inpatient treatment. Approved prescription medication causing "false positive" of another drug. Positives resulting from alcohol-producing microorganisms associated with participant's diabetes. Retest was negative.		
February	830	81	1 2 1 9 65 1 1	Participant relapsed. (#3 on Relapse Report) Participant's continued relapse. (#1 on Relapse Report) One participant ongoing relapse from December 2006 (as above). Approved prescriptions other than Naltrexone by case manager. Approved prescriptions by case manager for Naltreoxne. Positives resulting from alcohol-producing microorganisms associated with participant's diabetes. Determined not a relapse. Retest was negative.		
March	827 <b>2498</b>	91 <b>250</b>	1 13 64 3 3 4 1 2	Participant relapsed. (#4 on Relapse Report) Approved prescriptions other than Naltrexone by case manager. Approved prescriptions by case manager for Naltreoxne. New (3) participants, initial positive – sent to inpatient treatment. New participant, first three tests were positive – sent to inpatient treatment. Positives resulting from alcohol-producing microorganisms associated with participant's diabetes. Retest was negative. Pending investigation (2 participants).		
IOIAL	2490	250	250			
		EST RESULT				
<b>Month</b> 2007	Total # o	of lests Tot	al Negative- Dil Results	ute Number of Negative-Dilute Results	Comments	
January	84	1	5	5	Case Managers notified and retesting ordered.	
February	83	0	3	3	Case Managers notified and retesting ordered.	
March	82	7	2	2	Case Managers notified and retesting ordered.	
TOTAL	249	00	10	10		

## Data on Urine Tests Results – 3<sup>rd</sup> Quarter January – March 2007

2007 January	of Tests	Defeated Deputs		Comments
January		Rejected Results	or Rejected Results	
	841	9	1	Immunoassay Interference.
			1	GC/MS Interference (other compound interfering).
			1	Abnormal specimen odor.
			1	The sample leaked in transport.
			1	Possible Oxidant Activity.
			4	Insufficient volume due to lab using entire vial prior to completing the test.
February	830	14	1	Immunoassay Interference.
			1	Collector name/Signature not on Chain of Custody form; retesting ordered.
			2	Lab claims the specimen ID number mismatch/missing
			2	The sample leaked in transport.
ļ			1	Possible Oxidant Activity.
			7	Insufficient volume due to lab using entire vial prior to completing the test.
March	827	9	1	The sample leaked in transport.
			4	Insufficient volume due to lab using entire vial prior to completing the test.
			2	Possible Oxidant Activity.
			2	Collector name/Signature not on Chain of Custody form; retesting ordered.
TOTAL	2498	32	32	